Alan Green talks markets, Eddie Stobart #ESL, Cadence Minerals #KDNC & Tiziana Life #TILS on the UK Investor Mag podcast
Alan Green discusses markets, Eddie Stobart #ESL, Cadence Minerals #KDNC & Tiziana Life #TILS with Jonathan Roy on the UK Investor Mag podcast.
Tiziana Life Sciences #TILS – Block Listing Application and “At The Market” Sales Agreement
London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that that it has entered into an “At […]
Mail on Sunday Market Watchlist – Tiziana Life Sciences #TILS
There has been a scramble among AIM biotech companies to come up with a potential treatments for Coronavirus. One of the firms is Tiziana Life Sciences #TILS, listed on AIM and Nasdaq. The shares were in demand on Thursday when it said it had developed new technology to treat COVID-19 infections.
Tiziana Life Sciences #TILS – Develops Novel Investigational Treatment For Patients Infected with COVID-19
New York/London — April 9, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into […]
Alan Green talks market crash, Oil, Banks, Insurers and Coronavirus on the UK Investor Magazine podcast
Alan Green talks market crash, Oil, Banks, Insurers and Coronavirus with Jonathan Roy on the UK Investor Magazine podcast. Stocks covered include Shell #RDSB, #Aviva #AV, Legal & General #LGEN, Novacyt #NCYT, Tiziana Life #TILS and others.
Tiziana Life Sciences #TILS – Announces Closing of Offering and Resulting Total Voting Rights
London, New York 16 March 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the closing of its underwritten follow-on public offering (the […]
Alan Green talks market crash, Tiziana Life #TILS, Destiny Pharma #DEST, Open Orphan #ORPH & Cadence Minerals #KDNC on Vox Markets podcast
Alan Green discusses the market crash, Tiziana Life #TILS, Destiny Pharma #DEST, Open Orphan #ORPH & Cadence Minerals #KDNC with Justin Waite on the Vox Markets podcast. Interview is 35 minutes 40 seconds in.
Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million
New York and London, March 12, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the “Offering”) […]
Tiziana Life Sciences developing TZLS-501 as a potential treatment for Coronavirus patients
Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TSLA / AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure. Tiziana, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of […]
Tiziana Life Sciences (Nasdaq: TLSA; AIM: TILS) – TZLS-501 Potential Treatment of Certain Patients Infected with Coronavirus COVID-19
New York/London, March 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus […]